Neurodegenerative tauopathies

Annual Review of Neuroscience

Volumn 24, Issue , 2001, Pages 1121-1159

  Lee, V M Y ^a   Goedert, M ^a   Trojanowski, J Q ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Filamentous deposits; Frontotemporal dementia; Mutation; Neurodegenerative disease; Pathology; Tau protein

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CHROMOSOME 17; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DNA POLYMORPHISM; FRONTOTEMPORAL DEMENTIA; GENE MUTATION; HUMAN; NEUROPATHOLOGY; PARKINSONISM; PATHOGENESIS; PICK PRESENILE DEMENTIA; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; REVIEW;

ANIMALS; BRAIN; BRAIN DISEASES; DEMENTIA; HUMANS; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 0034940160     PISSN: 0147006X     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.neuro.24.1.1121     Document Type: Review

References (256)

1. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5
2. Structure and novel exons of the human tau gene
3. The tau mutation (va1337met) disrupts cytoskeletal networks of microtubules
4. Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene
5. Quantitative neurohistological features of frontotemporal degeneration
6. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations
7. Role of glycosaminoglycans in determining the helicity of paired helical filaments
8. Association of an extended haplotype in the tau gene with progressive supranuclear palsy
9. Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias
10. Phosphorylation of tau proteins to a state like that in Alzheimer's brain is catalyzed by a calcium/calmodulin-dependent kinase and modulated by phospholipids
11. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5
12. Direct genetic evidence for involvement of tau in progressive supranuclear palsy
13. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding
14. Regulated phosphorylation and dephosphorylation of tau protein: Effects on microtubule interaction, intracellular trafficking and neurodegeneration
15. The distribution of tau in the mammalian central nervous system
16. A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)
17. Chromosome 17 and hereditary dementia: Linkage studies in three nonAlzheimer families and kindreds with late-onset FAD
18. The tau gene in progressive supranuclear palsy: Exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases
19. A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads
20. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding
21. Mise en évidence immunologique de la protéine tau au niveau des lésions de dégénérescence neurofibrillaire de la maladie d'Alzheimer
22. Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease
23. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders
24. Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease
25. Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau
26. Tau protein binds to microtubules through a flexible array of distributed weak sites
27. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice
28. Overexpression of 4R-tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease
29. Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17
30. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly
31. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin
32. The Croonian Lecture 1998. Identification of a protein kinase cascade of major importance in insulin signal transduction
33. Genetic evidence for the involvement of tau in progressive supranuclear palsy
34. Pick's disease. Histological and clinical correlations
35. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
36. Primary structure of high molecular weight tau present in the peripheral nervous system
37. Straight and paired helical filaments in Alzheimer disease have a common structural unit
38. Abnormal tau-containing filaments in neurodegenerative diseases
39. The microtubule binding repeats of tau protein assemble into filaments like those found in Alzheimer's disease
40. Image reconstruction of the Alzheimer paired helical filament
41. Mutations in tau reduce its microtubule binding properties in intact cells and affect its phosphorylation
42. Specific pathological Tau protein variants characterize Pick's disease
43. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation
44. A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy
45. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions
46. Pick's disease: A modern approach
47. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy
48. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau
49. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption
50. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state
51. Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcineurin and phosphatase-2A
52. Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements
53. Determinants of 4 repeat tau expression: Coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion
54. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes
55. Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism
56. Identification of a novel polymorphism in the promoter region of the tau gene highly associated to progressive supranuclear palsy in humans
57. Widespread cytoskeletal pathology characterizes corticobasal degeneration
58. Epitope expression and hyperphosphorylation of tau protein in corticobasal degeneration: Differentiation from progressive supranuclear palsy
59. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration
60. Abnormal tau proteins in progressive supranuclear palsy. Similarities and differences with the neurofibrillary degeneration of the Alzheimer type
61. Frontotemporal dementia and parkinsonism linked to chromosome 17: A consensus conference
62. Abnormal microtubule packing in processes of SF9 cells expressing the FTDP- 17 V337M tau mutation
63. A nucleated assembly mechanism of Alzheimer paired helical filaments
64. In vitro polymerization of tau protein monitored by laser light scattering: Method and application to the study of FTDP-17 mutants
65. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein
66. Complex regulation of tau exon 10, whose missplicing causes frontotemporal dementia
67. High molecular weight tau: Preferential localization in the peripheral nervous system
68. RNA sequestration to pathological lesions of neurodegenerative diseases
69. 1. Implications for Alzheimer's disease
70. Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases
71. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization
72. Effects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments
73. The abnormal phosphorylation of tau protein at Ser202 in Alzheimer disease recapitulates phosphorylation during development
74. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase
75. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans
76. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations
77. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms
78. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system
79. Tau gene mutation in familial progressive subcortical gliosis
80. Filamentous nerve cell inclusions in neurodegenerative diseases
81. Molecular dissection of the paired helical filament
82. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease
83. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: Differential expression of tau protein mRNAs in human brain
84. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau
85. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly
86. Identification of a novel microtubule binding and assembly domain in the developmentally regulated interrepeat region of tau
87. Tau filament formation in transgenic mice expressing P301L tau
88. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform
89. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis
90. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau
91. 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10
92. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
93. Domains of tau protein and interactions with microtubules
94. Human tau filaments induce microtubule and synapse loss in an in vivo model of neurofibrillary degenerative disease
95. Human tau becomes phosphorylated and forms filamentous deposits when overexpressed in lamprey central neurons in situ
96. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase
97. Altered microtubule organization in small-calibre axons of mice lacking tau protein
98. Amyloid deposition as the central event in the aetiology of Alzheimer's disease
99. Alzheimer-like changes in microtubule-associated protein tau induced by sulfated glycosaminoglycans. Inhibition of microtubule binding, stimulation of phosphorylation, and filament assembly depend on the degree of sulfation
100. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein
101. Tau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly
102. FTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10
103. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy)
104. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging
105. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: A genetic and clinicopathological study of three Dutch families
106. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation
107. Progressive supranuclear gaze palsy is in linkage disequilibrium with the tau and not the alpha-synuclein gene
108. Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains
109. The tau gene A0 allele and progressive supranuclear palsy
110. Unique Alzheimer's disease paired helical filament specific epitopes involve double phosphorylation at specific sites
111. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
112. Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons
113. Tau-based neurofibrillary lesions
114. Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP- 17
115. Frequency of tau mutations in three series of non-Alzheimer's degenerative dementia
116. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
117. Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21-22 (FTDP-17): Duke Family 1684
118. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
119. A distinct familial presenile dementia with a novel missense mutation in the tau gene
120. Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice
121. Identification of the 23 kDa subunit of tau protein kinase II as a putative activator of cdk5 in bovine brain
122. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform
123. Age dependent induction of congophilic neurofibrillary inclusions in tau transgenic mice
124. Neuronal and glial tau-positive inclusions in diverse neurologic diseases share common phosphorylation characteristics
125. Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17
126. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments
127. Fetal-type phosphorylation of the tau in paired helical filaments
128. Paired helical filaments in electron microscopy of Alzheimer's disease
129. A cdc2-related kinase PSSALRE/cdk5 is homologous with the 30 kDa subunit of tau protein kinase II, a proline-directed protein kinase associated with microtubule
130. Familial frontotemporal dementia with a P301L tau mutation in Japan
131. Tau-positive glial inclusions in progressive supranuclear palsy, corticobasal degeneration and Pick's disease
132. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy
133. The carboxyl third of tau is tightly bound to paired helical filaments
134. Epitopes that span the tau molecule are shared with paired helical filaments
135. Ultrastructure and biochemical composition of paired helical filaments in corticobasal degeneration
136. Calpain-dependent proteolytic cleavage of the p35 cyclin-dependent kinase 5 activator to p25
137. The microtubule binding domain of tau protein
138. Neurotoxicity induces cleavage of p35 to p25 by calpain
139. A68: A major subunit of paired helical filaments and derivatized forms of normal tau
140. Hereditary dysphasic disinhibition dementia: A frontotemporal dementia linked to 17q21-22
141. Paullones are potent inhibitors of glycogen synthase kinase-3β and cyclin-dependent kinase 5/p25
142. A brain-specific activator of cyclin-dependent kinase 5
143. Neuronal cdc2-like kinase
144. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein
145. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein tau
146. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease
147. Frontotemporal dementia with novel tau pathology and a Glu342Val tau gene mutation
148. Phosphorylation by cAMP-dependent protein kinase inhibits the degradation of tau by calpain
149. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop
150. Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes
151. Lithium reduces tau phosphorylation: Effects in living cells and in neurons at therapeutic concentrations
152. Phosphorylation of tau by glycogen synthase kinase-3 beta in intact mammalian cells: The effects on the organization and stability of microtubules
153. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
154. Clinical and neuropathological criteria for frontotemporal dementia
155. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes
156. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau
157. Dementia of frontal type and dementias with subcortical gliosis
158. Spinal cord neurofibrillary tangles of Guamanian amyotrophic lateral sclerosis and parkinsonism-dementia complex: An immunohistochemical study
159. Stable expression in Chinese hamster ovary cells of mutated tau genes causing frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17)
160. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau
161. The phosphorylation state of tau in the developing rat brain is regulated by phosphoprotein phosphatases
162. Selective destruction of stable microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human neurons
163. Tau pathology in a family with dementia and a P301L mutation in tau
164. Corticobasal degeneration: A disease with widespread appearance of abnormal tau and neurofibrillary tangles, and its relation to progressive supranuclear palsy
165. Hyperphosphorylation of tau in PHF
166. The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases
167. Mutation in the tau exon 10 splice site region in familial frontotemporal dementia
168. Classic and generalized variants of Pick's disease: A clinicopathological, ultrastructural, and immunocytochemical comparative study
169. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
170. Immunocytochemical and ultrastructural studies of Pick's disease
171. Familial multiple-system tauopathy with presenile dementia is localized to chromosome 17
172. Tau gene mutation G389R causes a tauopathy with abundant Pick body-like inclusions and axonal deposits
173. Accelerated filament formation from tau protein with specific FTDP-17 missense mutations
174. From genotype to phenotype: A clinical pathological, and biochemical investigation of frontotemporal dementia and parkinsonism (FTDP-17) caused by the P301L tau mutation
175. Processing of cdk5 activator p35 to its truncated form (p25) by calpain in acutely injured neuronal cells
176. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2
177. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
178. The FTDP-17-linked mutation R406W abolishes the interaction of phosphorylated tau with microtubules
179. Polymerization of tau into filaments in the presence of heparin: The minimal sequence required for tau-tau interaction
180. Pick's disease is associated with mutations in the tau gene
181. Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau
182. Tau is a candidate gene for chromosome 17 frontotemporal dementia
183. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein
184. Pick's disease: Hyperphosphorylated tau protein segregates to the somatoaxonal compartment
185. Corticodentatonigral degeneration with neuronal achromasia: A progressive disorder in late adult life
186. Corticodentatonigral degeneration with neuronal achromasia 2
187. The neuropathology of a chromosome 17-linked autosomal dominant parkinsonism and dementia ("pallido-ponto-nigral degeneration")
188. Clinical and neuropathological diagnosis of frontotemporal dementias
189. Reactivating kinase/p38 phosphorylates tau protein in vitro
190. Stress-activated protein kinase/c-jun N-terminal kinase phosphorylates tau protein
191. Tau gene mutation K257T causes a tauopathy similar to Pick's disease
192. Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients
193. High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in the Netherlands
194. Electron microscopic study of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome
195. Missense point mutations of tau to segregate with FTDP-17 exhibit site-specific effects on microtubule structure in COS cells: A novel action of R406W mutation
196. Neurofibrillary tangles in progressive supranuclear palsy contain the same tau epitopes identified in Alzheimer's disease PHFtau
197. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments
198. Structural studies of tau protein and Alzheimer paired helical filaments show no evidence for beta-structure
199. Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5
200. Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases
201. Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: Tau pathologies with exclusively "exon 10" isoforms
202. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau
203. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues
204. The exon splicing silencer in human immunodeficiency virus type 1 Tat exon 3 is bipartite and acts early in spliceosome assembly
205. Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by nonproline-dependent protein kinases
206. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome
207. Interaction of neuronal cdc2 like protein kinase with microtubule associated protein tau
208. A novel pool of protein phosphatase 2A is associated with microtubules and is regulated during the cell cycle
209. Molecular interactions among protein phosphatase 2A, tau, and microtubules. Implications for the regulation of tau phosphorylation and the development of tauopathies
210. FTDP-17: An early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation
211. Frontotemporal dementia and parkinsonism linked to chromosome 17: A new group of tauopathies
212. Comparison of the neurofibrillary pathology in Alzheimer's disease and familial presenile dementia with tangles
213. Tau pathology in two Dutch families with mutations in the microtubule-binding region of tau
214. Familial multiple system tauopathy with presenile dementia: A disease with abundant neuronal and glial tau filaments
215. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
216. A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies
217. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein
218. Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice
219. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: Expansion of the disease phenotype caused by tau gene mutations
220. Progressive supranuclear palsy
221. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
222. Involvement of tau protein kinase I in paired helical filament-like phosphorylation of the juvenile tau in rat brain
223. Lithium inhibits neurite growth and tau protein kinase I/glycogen synthase kinase-3β-dependent phosphorylation of juvenile tau in cultured hippocampal neurons
224. Polypurine sequences within a downstream exon function as a splicing enhancer
225. Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome
226. Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice
227. A new case of frontotemporal dementia and parkinsonism resulting from an intron 10 +3-splice site mutation in the tau gene: Clinical and pathological features
228. Fatal attraction: Abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia
229. Paired helical filament tau in Alzheimer's disease. The kinase connection
230. p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5
231. Natural methylamine osmolytes, trimethylamine N-oxide and betaine, increase tau-induced polymerization of microtubules
232. Phosphorylated tau can promote tubulin assembly
233. Phenotypic variation in hereditary frontotemporal dementia with tau mutations
234. Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17
235. Structural basis for recognition of the RNA major groove in the tau exon 10 splicing regulatory element by aminoglycoside antibiotics
236. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain
237. Biochemical mapping of neurofibrillary degeneration in a case of progressive supranuclear palsy: Evidence for general cortical involvement
238. Distinct FTDP-17 missense mutations in tau produce tau aggregates and other phathological phenotypes in transfected CHO cells
239. Assembly of tau protein into Alzheimer paired helical filaments depends on a local sequence motif ((306)VQIVYK(311)) forming beta structure
240. In vivo phosphorylation sites in fetal and adult rat tau
241. A protein factor essential for microtubule assembly
242. Localization of the gene for rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration to chromosome 17q21
243. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22
244. Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro
245. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimer's disease
246. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease
247. Molecular flexibility in microtubule proteins: Proton nuclear magnetic resonance characterization
248. Appearance of paired nucleated, tau-positive glia in patients with progressive supranuclear palsy brain tissue
249. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II
250. A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration
251. A novel mutation at posititon +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto)
252. Fibrillogenesis of tau: Insights from tau missense mutations in FTDP-17
253. Tau in paired helical filaments is functionally distinct from fetal tau: Assembly incompetence of paired helical filament-tau
254. Sequential phosphorylation of tau by glycogen synthase kinase-3β and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation
255. Loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia